Theralase Technologies (CVE:TLT) Reaches New 1-Year Low at $0.16

Theralase Technologies Inc. (CVE:TLT) reached a new 52-week low on Monday . The stock traded as low as C$0.16 and last traded at C$0.16, with a volume of 96100 shares traded. The stock had previously closed at C$0.16.

Theralase Technologies Stock Performance

The company has a quick ratio of 3.40, a current ratio of 1.22 and a debt-to-equity ratio of 25.07. The company has a market cap of C$36.45 million, a P/E ratio of -8.00 and a beta of 1.66. The business has a fifty day moving average of C$0.19 and a 200 day moving average of C$0.19.

Theralase Technologies (CVE:TLT) last released its quarterly earnings results on Wednesday, March 27th. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.36 million for the quarter. On average, equities analysts predict that Theralase Technologies Inc. will post -0.05 EPS for the current year.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.